WASHINGTON (REUTERS) – Pfizer and its accomplice BioNTech stated on Tuesday (April 26) that they’d submitted an software to the US well being regulator for the authorisation of a booster dose of their Covid-19 vaccine for kids aged 5 to 11 years.
The firms earlier this month reported information from a mid-to-late stage research displaying a 3rd dose of their shot elevated safety in opposition to the unique coronavirus model and the Omicron variant amongst kids within the age group.
It is unclear how a lot demand there’s for a 3rd vaccine dose within the age group.
Just 28 per cent of kids aged 5 to 11 years – round 8.2 million – are totally vaccinated, in line with information from the US Centers for Disease Control and Prevention.
There has additionally been some skepticism on the necessity for boosters in younger kids given the diminished danger of extreme an infection and hospitalisation within the age group.
Pfizer and BioNTech have filed for the clearance of a 10-microgram booster dose for kids 5 to 11 years. Adults obtain a 30-microgram dose of the vaccine.
The main two-dose Covid-19 shot from Pfizer and BioNTech was authorised within the United States for kids 5 to 11 years in October.
The US Food and Drug Administration (FDA) in January authorised the use of a 3rd dose of the businesses’ Covid-19 vaccine for kids ages 12 to fifteen. The company has additionally authorised a booster shot for kids aged 5 by 11 years who’re immunocompromised.
Rival Moderna continues to be ready for a call from US regulators on the use of its main Covid-19 sequence amongst age teams below 18 years.
It plans to submit an software to the FDA for the authorisation of its Covid-19 vaccine amongst kids six months to 5 years by the tip of April.